Open-label, multiple-dose study of the safety and efficacy of RN624 in adults with pain due to osteoarthritis of the knee.

Trial Profile

Open-label, multiple-dose study of the safety and efficacy of RN624 in adults with pain due to osteoarthritis of the knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Pfizer; Rinat Neuroscience
  • Most Recent Events

    • 30 Sep 2008 Planned number of patients changed from 150 to 104 as reported by ClinicalTrials.gov.
    • 16 Jan 2008 Status changed from recruiting to in progress.
    • 03 Jan 2008 The expected completion date for this trial is now 1 Feb 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top